Lanham O'Dell & Company, Inc. Ocugen, Inc. Transaction History
Lanham O'Dell & Company, Inc.
- $257 Million
- Q3 2025
A detailed history of Lanham O'Dell & Company, Inc. transactions in Ocugen, Inc. stock. As of the latest transaction made, Lanham O'Dell & Company, Inc. holds 140,000 shares of OCGN stock, worth $207,200. This represents 0.09% of its overall portfolio holdings.
Number of Shares
140,000
Previous 130,000
7.69%
Holding current value
$207,200
Previous $126,000
80.95%
% of portfolio
0.09%
Previous 0.06%
Shares
6 transactions
Others Institutions Holding OCGN
# of Institutions
108Shares Held
64.3MCall Options Held
604KPut Options Held
253K-
Black Rock Inc. New York, NY17.9MShares$26.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA14.8MShares$21.9 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny5.06MShares$7.49 Million0.0% of portfolio
-
Gmt Capital Corp Atlanta, GA4.15MShares$6.15 Million0.17% of portfolio
-
Geode Capital Management, LLC Boston, MA3.49MShares$5.16 Million0.0% of portfolio
About Ocugen, Inc.
- Ticker OCGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 216,566,000
- Market Cap $321M
- Description
- Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmento...